FINWIRES · TerminalLIVE
FINWIRES

SHA:688428

6 stories mentioning SHA:688428Updated 15d ago

Every FINWIRES story that references SHA:688428, newest first.

Asia

InnoCare Pharma's Phase III Trial of Fadeucravacitinib Meets Primary Endpoint

InnoCare Pharma (HKG:9969, SHA:688428) said the Phase III clinical trial of fadeucravacitinib met its primary endpoint, according to a Hong Kong bourse disclosure on Monday.The pharmaceutical company's Hong Kong shares rose 1% during Tuesday's midday trade.The drug was tested as a treatment for patients with moderate-to-severe plaque psoriasis.The drug's safety profile was consistent with previous clinical studies and no new safety signals were identified. Results from the study will be presented at upcoming international scientific congresses and in medical journals.

HKG:9969SHA:688428
Asia

InnoCare Pharma's Phase II Study of Vitiligo Drug Shows Consistent Safety, Efficacy

InnoCare Pharma's (HKG:9969, SHA:688428) phase II portion of the ongoing phase II/III adaptive study of soficitinib met its primary endpoint.The drug showed meaningful improvements versus placebo for the treatment of adult patients with non-segmental vitiligo, according to a Thursday Hong Kong bourse filing.Treatment with the drug also demonstrated consistent efficacy across multiple secondary endpoints.The drug's safety profile is consistent with previous studies.

HKG:9969SHA:688428
Asia

InnoCare Pharma Gets Acceptance for ITP New Drug Application; Shares Up 3%

InnoCare Pharma (SHA:688428, HKG:9969) said China's drug regulator accepted the new drug application for orelabrutinib for treating primary immune thrombocytopenia (ITP), according to a Friday filing with the Shanghai bourse.Shares of the drugmaker rose 3% in recent trade on the Hong Kong bourse.

HKG:9969SHA:688428
Asia

InnoCare Pharma to Vest Over 2.4 Million Shares for 74 Employees

InnoCare Pharma (SHA:688428, HKG:9969) approved the vesting of shares under a stock incentive plan and the cancellation of granted but unvested shares, according to a Tuesday filing with the Shanghai bourse.The company will vest more than 2.4 million restricted shares granted to 74 recipients.InnoCare will cancel 157,000 shares that are granted but unvested, as the four recipients have departed InnoCare, and cancel 167,000 restricted shares.

HKG:9969SHA:688428
Asia

InnoCare Pharma Unit Doses First Patient in Autoimmune Disease Drug Trial

InnoCare Pharma Ltd. (HKG:9969) unit InnoCare Pharma Inc. dosed the first subject in a phase 1 trial of ICP-054 in China.Preclinical data shows the potential of ICP-054 to be a differentiated oral therapy for autoimmune and inflammatory diseases associated with dysregulated IL-17 signaling, according to a Wednesday Hong Kong bourse filing.The Hong Kong-listed drugmaker is developing the drug in partnership with Zenas BioPharma.

HKG:9969SHA:688428
Asia

InnoCare Pharma's Q1 Profit Soars 489%

InnoCare Pharma (SHA:688428, HKG:9969) recorded a 489% surge in attributable profit in the first quarter of 2026 to 105.8 million yuan from 18 million yuan a year prior, according to a Thursday Hong Kong bourse filing.Basic EPS rose to 0.06 yuan in the three months from 0.01 yuan in the corresponding period of the previous fiscal year.Operating revenue jumped 39% to 528.6 million yuan from 381.3 million yuan in the year-ago period, driven by the volume growth and new contributions from various products, as well as milestone payments under a license agreement with Zenas BioPharma.

HKG:9969SHA:688428

Track with the FINWIRES app suite

FolioX
FolioX
Track SHA:688428 in your portfolio
WheelAI
WheelAI
Analyze SHA:688428 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on SHA:688428